PTPN11 and mast cell leukemia: In both erythroblast and mast cell leukemia cell lines, SHP2 silencing led to reduced Ras/MEK/ERK pathway activation, upregulation of Bim, and apoptosis [28, 29], which was consistent with our results in SHP2 knock-out (KO) mast cells [22].